Researchers explore the cellular and molecular adaptations associated with human secondary lymphoid tissue in adults during ...

Abbreviations: APRIL = a proliferation-inducing ligand; ASC = antibody-secreting cell; B = B cell; BAFF = B-cell-activating factor; BAFF-R = B-cell-activating factor receptor; BCMA = B-cell ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Intra-ImmuSG seeks to develop a safer and more effective cancer therapy via a combination of a targeted therapy and immunotherapy.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

It is thought that CD38-expressing cells contribute to disease through the secretion of antibodies that subsequently form immune complexes that deposit in the kidneys and cause inflammation and ...

Upon glial depletion, Paneth cell secretion is disrupted leading to dysmorphic granules ... goat [HINGS] or donkey serum in PBS), incubated overnight at 4°C in primary antibody/blocking solution, ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...

Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.